High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach.
High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further reduction in toxicity and increased patient satisfaction is necessary. Fifty-three patients with MBC were enrolled in a feasibility study at our cancer centre with a three-step approach to outpatient observation after HDCT and ABC transplantation discharging our patients from hospital 6 days after reinfusion of ABC, 1 day after reinfusion of ABC and 1 day prior to reinfusion of ABC. The supportive care consisted of the use of 5-HT3 antagonists for nausea and vomiting, DMSO depletion, through body hygiene, prophylactic antibiotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treatment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The median hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient post-transplant observation.
Glück
S
S
Northeastern Ontario Regional Cancer Centre, Sudbury, Canada.
des Rochers
C
C
Cano
C
C
Dorreen
M
M
Germond
C
C
Gill
K
K
Lopez
P
P
Sinoff
C
C
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care / Q000379:methods*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001804:Blood Transfusion, Autologous / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010351:Patient Discharge; D010359:Patient Readmission; D010865:Pilot Projects; D011446:Prospective Studies